STOCK TITAN
  1. Home
  2. Sec-filings
  3. ELVN
  4. [Form 4] Enliven Therapeutics, Inc. Insider Trading Activity

Enliven (ELVN) CEO Sells 6,000 Shares Under 10b5-1 Plan

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Samuel Kintz, President & CEO and director of Enliven Therapeutics (ELVN), reported two open-market sales under a Rule 10b5-1 plan adopted November 15, 2024. On 09/17/2025 he sold 5,000 shares for a weighted-average price of $19.0946, leaving beneficial ownership of 922,892 shares of record held by The Kintz & Egan Trust Dated March 30, 2019 for which he is trustee. On 09/19/2025 he sold 1,000 shares for a weighted-average price of $20.25, reducing beneficial ownership to 921,892 shares. The Form 4 was executed by power of attorney on 09/19/2025 and discloses the plan-based nature of the trades and willingness to provide per-trade price details upon request.

Positive

  • Sales were executed under a Rule 10b5-1 trading plan, adopted November 15, 2024, which provides pre-established, compliant trading procedures.
  • Filing discloses weighted-average prices and offers per-trade details upon request, indicating transparency in the reported transactions.

Negative

  • Insider disposed of 6,000 shares, reducing reported beneficial ownership from 928,892 to 921,892 (as shown after the second sale).
  • Sales involved multiple trade prices, requiring additional per-trade detail to fully reconcile execution timing and quantities.

Insights

TL;DR: Insider sales were executed under a pre-established Rule 10b5-1 plan, demonstrating adherence to structured trading protocols.

The filing shows the companys President & CEO, Samuel Kintz, executed two small open-market dispositions totaling 6,000 shares pursuant to a 10b5-1 trading plan adopted November 15, 2024. Reporting that shares are held in a trust for which he serves as trustee clarifies the beneficial ownership chain. The filings disclosure of weighted-average prices and offer to provide per-trade details is consistent with high transparency standards for insider reporting.

TL;DR: Transactions are routine insider sales under a preset plan and do not by themselves indicate a material change in ownership.

The Form 4 records sales of 5,000 shares at a weighted average of $19.0946 and 1,000 shares at $20.25, leaving reported beneficial holdings of 921,892 shares after the second sale. The use of a Rule 10b5-1 plan and the trustee-held record ownership reduce ambiguity about timing and intent, but the filing does not provide any new operational or financial information about Enliven Therapeutics that would affect valuation.

Insider Kintz Samuel
Role PRESIDENT AND CEO
Sold 6,000 shs ($116K)
Type Security Shares Price Value
Sale Common Stock 1,000 $20.25 $20K
Sale Common Stock 5,000 $19.0946 $95K
Holdings After Transaction: Common Stock — 921,892 shares (Indirect, See footnote)
Footnotes (1)
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. This transaction was executed in multiple trades at prices ranging from $18.56 to $19.51. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee. This transaction was executed in multiple trades at prices ranging from $20.015 to $20.035. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kintz Samuel
(Last) (First) (Middle)
C/O ENLIVEN THERAPEUTICS, INC.
6200 LOOKOUT ROAD
(Street)
BOULDER CO 80301
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
PRESIDENT AND CEO
3. Date of Earliest Transaction (Month/Day/Year)
09/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/17/2025 S(1) 5,000 D $19.0946(2) 922,892 I See footnote(3)
Common Stock 09/19/2025 S(1) 1,000 D $20.25(4) 921,892 I See footnote(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
2. This transaction was executed in multiple trades at prices ranging from $18.56 to $19.51. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.
4. This transaction was executed in multiple trades at prices ranging from $20.015 to $20.035. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
/s/ Ben Hohl, by power of attorney 09/19/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did ELVN report on the Form 4?

The Form 4 reports that Samuel Kintz sold 5,000 shares on 09/17/2025 at a weighted-average price of $19.0946 and 1,000 shares on 09/19/2025 at a weighted-average price of $20.25.

Were the ELVN insider sales part of a trading plan?

Yes. The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024.

How many ELVN shares does Samuel Kintz beneficially own after these transactions?

Following the reported transactions, the filing shows beneficial ownership of 921,892 shares (held of record by The Kintz & Egan Trust Dated March 30, 2019).

Who signed the Form 4 for the reporting person?

The Form 4 was signed /s/ Ben Hohl, by power of attorney on 09/19/2025.

Do the reported prices reflect single trades or averages?

The reported prices are weighted-average sale prices reflecting multiple trades; the filing states per-trade details are available upon request.